Study partners should be required in preclinical Alzheimer’s disease trials

BACKGROUND: In an effort to intervene earlier in Alzheimer’s disease (AD), clinical trials are testing promising candidate therapies in preclinical disease. Preclinical AD trial participants are cognitively normal, functionally independent, and autonomous decision-makers. Yet, like AD dementia trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Grill, Joshua D., Karlawish, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719524/
https://www.ncbi.nlm.nih.gov/pubmed/29212555
http://dx.doi.org/10.1186/s13195-017-0327-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719524/
https://www.ncbi.nlm.nih.gov/pubmed/29212555
http://dx.doi.org/10.1186/s13195-017-0327-x

Ejemplares similares